It represents real science about when the peptide begins losing its ability to do what you are paying it to do
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
That means you chew it when you actually need it 15 minutes before the final climb, the last 4K of a 10K, or the moment pace starts slipping and it is already working by the time it matters
Its not FDA-approved for obesity
(Ver) Gaskins AJ, Chavarro JE
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer